Document:

<PAGE>

                                                                   EXHIBIT 10.30

                                  WELLMAN, INC.
                      2006 RESTRICTED STOCK GRANT AGREEMENT

SECTION I. GRANT

1.1 This Grant of Restricted Stock is made pursuant to and is subject to the
terms of the Wellman, Inc. Restricted Stock Plan which is effective June 1, 2004
(the "Plan"). All capitalized terms used herein and not defined in this document
have the meaning given such terms in the Plan. Each Grant made pursuant to the
Plan is an Award and shall be subject to all the terms and conditions of the
Plan, which are incorporated herein by reference.

1.2 EFFECTIVE DATE. This Grant is effective on January 13, 2006 (the "Effective
Date").

SECTION II. CERTAIN DEFINITIONS

2.1 ACCOUNTS PAYABLE are the Accounts Payable reported on the balance sheet for
the applicable period in the Company's Public Filings.

2.2 ACCRUED LIABILITIES are the Accrued Liabilities reported on the balance
sheet for the applicable period in the Company's Public Filings.

2.3 ADJUSTED EBITDA is the Gross Profit less SG&A Expense plus D&A. This means
other items such as restructuring, DOJ legal costs and CDO rebates are excluded.

2.4 AVERAGE NET ASSETS are the Net Assets for December 31st of the previous
fiscal year plus the Net Assets at the end of each fiscal period in the current
year divided by thirteen.

2.5 CASH is the cash reported on the balance sheet for the applicable period in
the Company's Public Filings.

2.6 CAUSE means, when used with respect to the termination of the employment of
the Executive by the Company, termination due to (a) an act or acts of personal
dishonesty taken by the Executive and intended to result in substantial personal
enrichment of the Executive at the expense of the Company; (b) the Executive's
continued failure to substantially perform his employment duties (other than any
such failure resulting from the Executive's incapacity due to physical or mental
illness) which are demonstrably willful and deliberate on the Executive's part
and which are not remedied in a reasonable period of time after receipt of
written notice from the Company; or (c) conviction of, or a

<PAGE>

plea of guilty or no contest by, the Executive to a crime that constitutes a
felony involving moral turpitude. No act or failure to act on the part of the
Executive shall be considered "willful" unless it is done, or omitted to be
done, by the Executive in bad faith or without reasonable belief that the
Executive's action or omission was in the best interests of the Company.

2.7 CIP is construction in progress reported on the balance sheet for the
applicable period in the Company's Public Filings.

2.8 CURRENT ASSETS are the current assets reported on the balance sheet for the
applicable period in the Company's Public Filings.

2.9 D&A is the depreciation and amortization reported on the statement of cash
flows for the applicable period in the Company's public filings but only to the
extent it reduces Gross Profit or increases SG&A Expense.

2.10 DISABILITY means that the Executive has been unable, for the period
specified in the Company's disability plan for senior executives, but not less
than a period of 180 consecutive days, to perform the Executive's duties under
this Agreement, as a result of physical or mental illness or injury.

2.11 EBITDA RETURN is a percentage which is calculated by dividing Adjusted
EBITDA for a fiscal year by the Average Net Assets.

2.12 ENVIRONMENTAL RESERVES are the estimated future environmental related
liabilities that are recorded on the balance sheet for the applicable period in
the Company's Pubic Filings.

2.13 GROSS PROFIT is the Gross Profit reported on the income statement for the
applicable period in the Company's Public Filings.

2.14 IDLE ASSETS are any property plant and equipment that has not been utilized
for 28 consecutive days on the last day of each Fiscal Period.

2.15 INITIAL RESTRICTED PERIOD means the period commencing on January 13, 2006
and ending on January 13, 2011.

2.16 LONG TERM RECEIVABLES are any amounts due from either current or former
customers that are included in Other Assets as reported in the Company's Public
Filings.

2.17 NET ASSETS are the Current Assets less Cash plus Net PP&E less CIP less
Idle Assets plus the Prepaid Raw Material Contract plus Long Term Receivables
less Accounts Payable less Accrued Liabilities less Environmental Reserves.

<PAGE>

2.18 NET PP&E is the Property Plant and Equipment less the related accumulated
depreciation reported on the balance sheet for the applicable period in the
Company's Public Filings.

2.19 PREPAID RAW MATERIAL CONTRACT is the amount related to a prepayment for a
raw material contract that are included in Other Current Asset and Other Assets
reduced by the related amortization, all as reported in the Company's Public
Filings.

2.20 PUBLIC FILINGS are the applicable Form 10-K or 10-Q that is initially filed
with the SEC.

2.21 RESTRICTED STOCK AWARD is the number of shares awarded to the individual in
this grant as provided in Section 3.1.

2.22 RESTRICTED PERIOD means either the Initial Restricted Period or a
Subsequent Restricted Period, as applicable.

2.23 RESTRICTED STOCK means shares of Common Stock which are issued by the
Company pursuant to this Grant Agreement and which are subject to forfeiture,
restrictions on transfer and other restrictions as are set forth in Section IV
hereof.

2.24 SG&A EXPENSE is the selling, general and administrative expense reported on
the income statement for the applicable period in the Company's Public Filings.

2.25 SUBSIDIARY means a corporation of which more than 50% of the total combined
voting power of all classes of stock entitled to vote is owned, directly or
indirectly, by Wellman, Inc.

2.26 UNVESTED RESTRICTED STOCK is Restricted Stock subject to the restrictions
set forth in subsection 4.1 (a) and (b).

Unless the context clearly requires otherwise, the masculine pronoun whenever
used shall include the feminine and neuter pronouns, the singular shall include
the plural and the plural shall include the singular.

SECTION III. AWARD

3.1 AWARD. The Committee has designated the person executing this Grant
Agreement as a Participant eligible to receive 20,000 shares of Restricted Stock
and this Grant is made subject to the terms and conditions in this Grant
Agreement and the Plan. No payment for such shares is required except pursuant
to Section 5.2.

3.2 ACCEPTANCE. By accepting this Grant of Restricted Stock the Participant
acknowledges and agrees that the shares of Restricted Stock are subject to the
terms and conditions of this Grant Agreement and the Plan.

<PAGE>

3.3 ADJUSTMENTS. In the event of any stock dividend, stock split, combination or
exchange of shares, merger, consolidation, spin-off or other distribution (other
than normal cash dividend) of the Company assets to stockholders, or any other
change affecting shares or the Company's capitalization, such adjustments as the
Committee in its discretion may deem appropriate to reflect such change or to
fairly preserve the intended benefits of the Plan shall be made. In addition,
any shares issued by the Company through the assumption or substitution of
outstanding stock awards or award commitments from an acquired company or other
entity shall not reduce the shares available for issuance under the Plan.

SECTION IV. TERMS OF RESTRICTED STOCK

4.1 TERMS OF RESTRICTED STOCK

(a) Prior to the expiration of the Restricted Period the Participant shall not
sell, transfer, pledge or otherwise encumber ("Transfer") the Restricted Stock
and any such Transfer shall be void. After the Restricted Period the Participant
shall not Transfer the Restricted Stock in any manner that could violate any
securities laws or result in short swing profits.

(b) The Participant shall not be entitled to delivery of a certificate
evidencing the shares of Restricted Stock until the expiration or termination of
the Restricted Period and the satisfaction of any and all other conditions
specified in this Grant Agreement.

(c) Any shares of Restricted Stock which are forfeited pursuant to this Grant
Agreement shall be cancelled and all rights of the Participant with respect to
such forfeited shares of Restricted Stock shall terminate without further
obligation on the part of the Company upon the occurrence of any of the events
set forth below in subsection 4.4.

4.2 CUSTODY OF SHARES OF RESTRICTED STOCK; RIGHTS WITH RESPECT TO STOCK.

(a) The Restricted Stock granted hereunder shall be issued and registered in the
Participant's name and shall be held by the Company during the Restricted
Period. The Company shall serve as attorney-in-fact for the Participant during
the Restricted Period with full power and authority in the Participant's name to
assign and convey to the Company any shares of Restricted Stock held by the
Company for such Participant if the Participant forfeits the shares under the
terms of this Grant Agreement. Each certificate representing shares of
Restricted Stock may bear a legend referring to this Grant Agreement and the
Plan and the risk of forfeiture of the shares of Restricted Stock and stating
that such shares of Restricted Stock are nontransferable until all restrictions
have been satisfied and the legend has been removed. Similarly, for Restricted
Stock shares held in book form, controls are in place to prevent the transfer of
such shares until the transfer agent has been notified by the Company that the
restrictions on those shares have lapsed.

<PAGE>

(b) During the Restricted Period, the Participant shall be a stockholder and
have all the rights of a stockholder with respect to such shares, including the
right to vote and receive all dividends or other distributions made or paid with
respect to such shares; provided, however, that such Restricted Stock and any
new, additional or different securities the Participant may become entitled to
receive with respect to such Restricted Stock by virtue of a stock split,
dividend or other change in the corporate or capital structure of the Company,
shall be subject to the restrictions described in this Grant Agreement.

4.3 DISTRIBUTION OF RESTRICTED STOCK.

If the Participant remains in the continuous employment or service of the
Company or any Subsidiary during the entire Restricted Period and otherwise does
not forfeit such shares of Restricted Stock pursuant to subsection 4.4 or any
other terms of the Grant Agreement, all restrictions applicable to the shares of
Restricted Stock shall lapse upon expiration or termination of the Restricted
Period, and a certificate or certificates of unrestricted Common Stock
representing the shares of Restricted Stock shall be delivered to the
Participant.

4.4 FORFEITURE.

(a) If a Participant's service or employment is terminated before the expiration
of the Restricted Period due to Disability or death of the Participant the
restrictions in subsection 4.1 (a) and (b) shall lapse. The certificate or
certificates representing the shares of Restricted Stock upon which the
restrictions have lapsed pursuant to this subsection 4.4(a) shall be delivered
to the Participant (or in the event of the Participant's death, to his estate)
after the Participant or his legal representative complies with the terms of
Section 5.2.

(b) On January 13th of each year that the Participant remains employed by the
Company, and the participant has Unvested Restricted Stock, the restrictions set
forth in subsection 4.1 (a) and (b) shall lapse with respect to the lesser of
20% of the Restricted Stock Award or the remaining Unvested Restricted Stock.

(c) In addition to the provisions of Section 4.4(a), if the Participant is an
employee of the Company on January 13th of any year when the Company files its
10-K for the prior year the participant has Unvested Restricted Stock, then the
restrictions set forth in subsection 4.1 (a) and (b) shall lapse with respect to
the lesser of the Additional Vesting Amount set forth in the table below or the
remaining Unvested Restricted Stock.

<TABLE>
<CAPTION>
EBITDA Return                        Additional Vesting Amount
-------------                        -------------------------
<S>                                  <C>
17% or more                                     20%
16.75% or more but less than 17%                15%
16.5% or more but less than 16.75%              10%
16.25% of more but less than 16.5%               5%
</TABLE>

<PAGE>

(d) If a Participant's service or employment is terminated by the Company or any
Subsidiary without Cause (other than as a result of death or Disability) in any
year and the Participant has Unvested Restricted Stock then the restrictions set
forth in subsection 4.1 (a) and (b) shall lapse with respect to the lesser of
the Unvested Restricted Stock or 20% of the Restricted Stock multiplied by a
fraction, the numerator of which shall be the number of months the Participant
has remained an employee (or in the service of) of the Company or a Subsidiary
since January 13th of the applicable year and the denominator of which shall be
12. Any remaining Unvested Restricted Stock will be forfeited.

(e) If a Participant's service or employment is terminated before the expiration
of the Restricted Period by the Company or any Subsidiary for Cause or by the
Participant (other than as a result of death or Disability), the Participant
shall forfeit all Restricted Stock.

4.5 CHANGE OF CONTROL. Upon any Change of Control all restrictions and
forfeiture provisions applicable to shares of Restricted Stock granted to the
Participant hereunder and not previously forfeited shall immediately lapse and
the certificate or certificates representing the Restricted Stock that were
granted to the Participants shall be delivered to the Participants as
unrestricted Common Stock, subject to the provisions of Section 5.2.

4.6 WAIVER OF RESTRICTIONS. The Committee, in its sole discretion, may at any
time waive any or all restrictions with respect to any shares of Restricted
Stock.

SECTION V. MISCELLANEOUS

5.1 TERMINATION. The provisions relating to the Restricted Stock granted
hereunder shall continue to apply with respect to all shares of Restricted Stock
until the restrictions lapse or the shares are forfeited.

5.2 WITHHOLDING. The Participant shall promptly pay to the Company any amount
necessary to satisfy applicable federal, state or local tax withholding
requirements attributable to the grant of Restricted Stock, the issuance of
Restricted Stock hereunder, or upon the vesting of or lapse of restrictions on
such Restricted Stock. If these amounts are not paid when requested, then at the
election of the Committee, shares of Restricted Stock with a value equal to the
amount of tax to be withheld shall be forfeited.

5.3 LEGAL AND OTHER REQUIREMENTS. The grant of Restricted Stock and the
distribution of shares of Restricted Stock provided by this Grant Agreement
shall be subject to the condition that if at any time the Company determines in
its discretion that the satisfaction of withholding tax or other tax
liabilities, or the listing, registration or qualification of any shares of
Restricted Stock upon any securities exchange or under any federal or state law,
or the consent or approval of any regulatory body, is necessary or desirable as
a condition of, or in connection with such grant or distribution, then in any

<PAGE>

such event, such grant or distribution shall not be effective unless such
liabilities have been satisfied or such listing, registration, qualification,
consent or approval shall have been effected or obtained free of any conditions
not acceptable to the Company.

<PAGE>

5.4 CHOICE OF LAW. This Grant Agreement and the Plan, their validity,
interpretation and administration and the rights and obligations of all Persons
having an interest therein shall be governed by and construed in accordance with
the laws of the State of Delaware, except to the extent that such laws may be
preempted by federal law.

5.5 FRACTIONAL SHARES. The Company shall not be required to issue or deliver any
fractional share of Restricted Stock issuable under this Grant Agreement.
Fractional shares will be paid in cash.

5.6 NO EMPLOYMENT CONTRACT. This Grant Agreement and the Plan shall not confer
upon the Participant any right to continued employment by the Company or in any
way interfere with the right of the Company to terminate the employment of any
Participant at any time.

5.7 SECTION 83(B) ELECTIONS. If a Participant files an election with the
Internal Revenue Service to include the fair market value of any shares of
Restricted Stock in gross income then the Participant shall promptly furnish the
Company with a copy of such election together with the amount of any federal,
state, local or other taxes required to be withheld (if any) to enable the
Company to claim an income tax deduction with respect to such election.

                                        Wellman, Inc.

                                        By: /s/ Keith R. Phillips
                                            ------------------------------------
                                        Name: Keith R. Phillips
                                        Title: Chief Financial Officer

Agreed to by:

Participant's Signature: /s/ Mark J. Ruday
                         ---------------------
Name (Please Print): Mark J. Ruday
Social Security Number: XXX-XX-XXXXexv10w1

 

EMPLOYMENT AGREEMENT

     THIS EMPLOYMENT AGREEMENT entered into as of the 9th day of March, 2006 (the
“Effective Date”), by and between PolyMedica Corporation (the “Company”), a Massachusetts
corporation, and Keith W. Jones, (the “Executive”) (hereinafter collectively referred to as the
“parties”).

     WHEREAS, the Executive is currently employed by the Company as its Chief Financial Officer and
during his employment has gained experience in all phases of the Company’s business;

     WHEREAS, the Company recognizes the Executive’s extraordinary experience and relationships in
the Company’s business and industry, and the Company desires to retain the services and employment
of the Executive;

     WHEREAS, the Executive and the Company are parties to an Employment Agreement dated February
9, 2005 and an Executive Retention Agreement dated February 9, 2005 (collectively, the “Prior
Agreements”); and

     WHEREAS, the Company and the Executive desire to enter into this Agreement which will replace
and supersede the Prior Agreements and will provide for the continued employment of the Executive
by the Company upon the terms and subject to the conditions set forth herein.

     NOW, THEREFORE, in consideration of the foregoing and the mutual promises contained herein,
the parties agree as follows:

     1.    Term. The initial term of employment under this Agreement will be for the period
commencing on the Effective Date and continuing in effect until March 8, 2009. The term of this
Agreement shall be extended for successive one (1) year terms at the end of the initial term and on
each anniversary thereafter unless the Company has provided written notice to the Executive at
least six (6) months before the end of a term that the Agreement shall not be extended (the initial
term and any extensions thereof, the “Term”). Notwithstanding the foregoing, the Executive’s
employment may be terminated during a Term as provided in Section 7 below.

     2.    Employment.

               (a)    The Executive will be employed as the Chief Financial Officer of the Company or in such
other position(s) as may be mutually agreed upon by the parties. The Executive will perform the
duties, undertake the responsibilities and exercise the authority customarily performed, undertaken
and exercised by persons employed in a similar executive capacity or as directed by PolyMedica’s
Chief Executive Officer or Board of Directors of the Company (the “Board”). The Executive shall
report directly to the Chief Executive Officer of PolyMedica.

1

 

               (b)    The Executive will devote his full working time, attention and skill to the performance of
his duties and responsibilities as an executive employee of the Company in a
trustworthy and professional manner, and will use his best efforts to promote the interests of
the Company. The Executive will not, without prior written approval of the Board, engage in any
other activities that would interfere with the performance of his duties as an employee of the
Company, are in violation of written policies of the Company, are in violation of applicable law,
or would create an actual or perceived conflict of interest with respect to the Executive’s
obligations as an employee of the Company. The Executive may (1) with advance notice to and
consent of the Board, serve on corporate, civil or charitable boards or committees; (2) deliver
lectures and teach at educational institutions; (3) serve as a personal representative or trustee;
(4) manage his personal, financial and legal affairs; and (5) invest personally in any business
where no conflict of interest exists between such investment and the business of the Company,
provided those activities do not require a material time commitment by the Executive or are
otherwise contrary to any provision of this Agreement.

     3.    Compensation. For so long as the Executive is employed by the Company under this
Agreement, the Executive shall be paid the following compensation:

               (a)    Base Salary. The Executive’s initial base salary will be $325,000 per annum (such
base salary, as may be adjusted from time to time in accordance with this Section, the “Base
Salary”), from which shall be deducted all required or authorized payroll deductions, including
state and federal withholdings. The Base Salary will be payable in accordance with the Company’s
customary payroll practices applicable to its executives. The Base Salary will be reviewed, and
may be adjusted, at least annually in a manner designated by the Board.

               (b)    Bonus. The Executive will be eligible for an annual bonus for each fiscal year of
his employment. Such bonus shall be based on a target equal to a percentage of Executive’s Base
Salary as set forth in the PolyMedica Executive Bonus Plan, or similar plan, as in effect from time
to time. The Board, or the Compensation Committee of the Board (the “Compensation Committee”), in
its sole discretion, shall establish the eligibility criteria for such annual bonus, which may
include Company financial projections and management goals specific to the Executive. Each bonus
earned by the Executive will be paid to the Executive on or before 2 1/2 months following the end
of (i) the Company’s fiscal year in which the applicable bonus was earned; or (ii) the calendar
year in which the applicable bonus was earned, as applicable.

               (c)    Stock Based Compensation. The Executive will be eligible to participate in
PolyMedica’s Employee Stock Purchase Plan and to be considered by the Compensation Committee for
grants or awards of stock options or other stock-based compensation under PolyMedica’s 2000 Stock
Incentive Plan or similar plans as in effect from time to time. All such grants or awards shall be
governed by the relevant plan documents and requirements and shall be evidenced by PolyMedica’s
then-standard form of stock option, restricted stock or other applicable agreement.

     4.    Employee Benefits. The Executive will be entitled to participate in all employee
benefit plans, practices and programs maintained by the Company and made available to

2

 

employees generally including, without limitation, all pension, retirement, profit sharing, savings, health,
hospitalization, disability, dental, life or travel accident insurance benefit plans, vacation and
sick leave in accordance with the terms of such plans, practices and programs as in effect from
time to time.

     5.    Executive Benefits. The Executive will be entitled to participate in all executive
benefit or incentive compensation plans now maintained or hereafter established by the Company for
the purpose of providing compensation and/or benefits to executives of the Company. Unless
otherwise provided herein or as otherwise determined by the Compensation Committee of the Board,
the Executive’s participation in such plans will be on the same basis and terms as other similarly
situated executives of the Company. No additional compensation provided under any of such plans
will be deemed to modify or otherwise affect the terms of this Agreement or any of the Executive’s
entitlements hereunder.

     6.    Reimbursements and Other Benefits.

               (a)    Expenses. The Company will pay all reasonable and properly documented expenses
incurred by the Executive in furtherance of the Company’s business in accordance with applicable
Company policies and procedures (“Expenses”), including, without limitation, traveling and
entertainment expenses, and will reimburse the Executive for all such reasonable expenses advanced
by him and not reimbursed prior to the date of this Agreement.

               (b)    Life Insurance. The Company will provide term life insurance on the life of the
Executive, for which the Executive shall designate the beneficiaries, with a death benefit equal to
150% of the Executive’s Base Salary.

               (c)    Vacation. The Executive may take four (4) weeks of paid vacation during each year
at such times as shall be consistent with PolyMedica’s vacation policies and, in PolyMedica’s
judgment, with PolyMedica’s vacation schedule for executives and other employees.

     7.    Termination and Compensation Upon Termination. The Executive’s employment
hereunder may be terminated under the following circumstances:

               (a)    Definitions.

                 (i) Cause. For purposes of this Agreement, “Cause” means:

                         (A)    a good faith finding by the Board that the Executive failed to substantially perform his
duties and obligations to the Company (other than a failure resulting from the Executive’s
incapacity because of a Disability, as defined in Section 7(a)(ii)), including but not limited to
one or more acts of gross negligence;

                         (B)    a good faith finding by the Board of a material breach of the Company’s Code of Conduct or
other policies and procedures; provided that, if such material breach is determined by the Board,
in its sole discretion, to be curable, the material breach is not

3

 

cured within 10 days after a
written demand for cure is received by the Executive from the Board which specifically identifies
the manner in which the Board believes the Executive has materially breached a provision of the
Company’s Code of Conduct or other written policies of the Company;

                         (C)    indictment or conviction (including the entry of a plea of guilty or nolo contendere by
the Executive) to any felony or any misdemeanor or other criminal
offense involving fraud, dishonesty, theft, breach of trust or moral turpitude or that
requires mandatory exclusion in any Federal health care program pursuant to 42 U.S.C. § 1320a-7(a)
during the Executive’s employment;

                         (D)    a good faith finding by the Board that the Executive willfully engaged in conduct which is
demonstrably and materially injurious to the Company, monetarily or otherwise;

                         (E)    a good faith finding by the Board that the Executive materially breached this Agreement or
the Confidentiality, Non-Competition/Non-Solicitation and Work Product Agreement incorporated by
Section 8;

                         (F)    the Executive’s exclusion, debarment or suspension from participation in any Federal
health care programs or in Federal procurement or nonprocurement programs; or

                         (G)    the Executive’s violation of the Securities Act of 1933 or the Securities Exchange Act of
1934.

                 (ii) Disability.

                         (A)    Except as set forth in Section 7(a)(ii)(B) below, for purposes of this Agreement,
“Disability” means a physical or mental illness, impairment or infirmity which renders the
Executive unable to perform the essential functions of his position, including his duties under
this Agreement, with reasonable accommodation, as determined by a physician selected by the Company
and acceptable to the Executive or the Executive’s legal representative, for at least one hundred
eighty (180) days during any 365-consecutive-day period.

                         (B)    Notwithstanding the foregoing, to the extent that any payment under this Agreement that is
subject to Code Section 409A may be triggered due to a Disability, “Disability” shall mean
Executive (A) is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment which can be expected to result in death or can be
expected to last for a continuous period of not less than twelve (12) months, or (B) is, by reason
of any medically determinable physical or mental impairment which can be expected to result in
death or can be expected to last for a continuous period of not less than twelve (12) months,
receiving income replacement benefits for a period of not less than three (3) months under a
Company-sponsored group disability plan.

4

 

               The Executive shall be entitled to the compensation and benefits provided for under this
Agreement for any period during the Term of this Agreement and prior to the establishment of the
Executive’s Disability during which the Executive is unable to work due to a physical or mental
illness, impairment or infirmity. Notwithstanding anything contained in this Agreement to the
contrary, the Executive will be entitled to return to his position with the Company as set forth in
this Agreement in which event no Disability of the Executive will be deemed to have occurred, until
the Termination Date specified in a Notice of Termination (as each term is hereinafter defined)
relating to the Executive’s Disability.

                 (iii) Change in Control. For purposes of this Agreement, “Change in Control” means
the occurrence of any of the following events:

                         (A)    the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3)
or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”)
of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person
beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) in excess
of 50% of either the then-outstanding shares of common stock of the Company (the “Outstanding
Company Common Stock”) or the combined voting power of the then-outstanding securities of the
Company entitled to vote generally in the election of directors (the “Outstanding Company Voting
Securities”); provided, however, that for purposes of this subsection (A), the following
acquisitions shall not constitute a Change in Control: (1) any acquisition of more than 50% of the
Outstanding Company Common Stock directly from the Company (excluding an acquisition pursuant to
the exercise, conversion or exchange of any security exercisable for, convertible into or
exchangeable for common stock or voting securities of the Company, unless the Person exercising,
converting or exchanging such security acquired such security directly from the Company or an
underwriter or agent of the Company); (2) any acquisition of more than 50% of the Outstanding
Company Common Stock by the Company; (3) any acquisition of more than 50% of the Outstanding
Company Common Stock by any employee benefit plan (or related trust) sponsored or maintained by the
Company or any corporation controlled by the Company; or (4) any acquisition by any Person who,
prior to such acquisition, already owned more than 50% of the Outstanding Company Common Stock or
Outstanding Company Voting Securities; or

                         (B)    such time as the majority of the members of the Board (or, if applicable, the board of
directors of a successor corporation to the Company) is replaced during any 12-month period
(commencing no earlier than the date of this Agreement) by directors whose appointment or election
is not endorsed by a majority of the members of the Board prior to the date of the appointment or
election; or

                         (C)    the consummation of a merger, consolidation, reorganization, recapitalization or statutory
share exchange involving the Company or a sale or other disposition of all or substantially all of
the assets of the Company in one or a series of transactions (a “Business Combination”), unless,
immediately following such Business Combination, all or substantially all of the individuals and
entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding
Company Voting

5

 

Securities immediately prior to such Business Combination beneficially own, directly
or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting
power of the then-outstanding securities entitled to vote generally in the election of directors,
respectively, of the resulting or acquiring corporation in such Business Combination (which shall
include, without limitation, a corporation which as a result of such transaction owns the Company
or substantially all of the Company’s assets either directly or through one or more subsidiaries)
in substantially the same proportions as their ownership, immediately prior to such Business
Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities,
respectively; or

                         (D)    approval by the stockholders of the Company of a complete liquidation or dissolution of
the Company, other than in a bankruptcy proceeding, provided that the liquidation or dissolution
otherwise meets the requirements of one of the events described in Sections 7(a)(iii)(A), (B) or
(C) above.

     In all respects, the definition of “Change in Control” shall be interpreted to comply with
Code Section 409A, and the provisions of Treasury Notice 2005-1, and any successor statute,
regulation and guidance thereto.

                (iv) Change in Control Date. For purposes of this Agreement, “Change in Control Date”
means (A) the first date during the Term on which a Change in Control occurs; or (B) the date
immediately prior to the date on which the Executive is terminated before a Change in Control if a
Change in Control occurs and it is reasonably demonstrated by the Executive that such termination
of employment (1) was at the request of a third party who has taken steps reasonably calculated to
effect a Change in Control; or (2) otherwise arose in connection with or in anticipation of a
Change in Control.

                (v) Good Reason. For purposes of this Agreement, “Good Reason” means:

                         (A)    a change in the Executive’s title or duties resulting in a material diminution of the
Executive’s status, authority or responsibilities;

                         (B)    a reduction in the Executive’s Base Salary;

                         (C)    the failure by the Company to (1) continue in effect any material compensation or benefit
plan or program (including without limitation any life insurance, medical, health and accident or
disability plan and any vacation or automobile program or policy) (a “Benefit Plan”) in which the
Executive participates or which is applicable to the Executive, unless an equitable arrangement
(embodied in an ongoing substitute or alternative plan) has been made with respect to such plan or
program; (2) continue the Executive’s participation in a Benefit Plan (or in such substitute or
alternative plan) on a basis not materially less favorable, both in terms of the amount of benefits
provided and the level of the Executive’s participation relative to other participants; or (3)
award cash bonuses to the Executive in amounts and in a manner substantially consistent with past
practice in light of the Company’s financial performance;

6

 

                         (D)    a change by the Company in the location at which the Executive performs his principal
duties for the Company to a new location that is both (1) outside a radius of 35 miles from the
Executive’s principal residence; and (2) more than 20 miles from the location at which the
Executive performed his principal duties for the Company as of the date this Agreement is executed
by the Executive;

                         (E)    a requirement by the Company that the Executive travel on Company business to a
substantially greater extent than as of the date this Agreement is executed by the Executive;

                         (F)    the failure of the Company to obtain the agreement from any successor to the Company to
assume and agree to perform this Agreement, as required by Section 11(a);

                         (G)    a purported termination of the Executive’s employment which is not effected pursuant to a
Notice of Termination satisfying the requirements of Section 7(c); or

                         (H)    any failure of the Company to pay or provide to the Executive any portion of the
Executive’s compensation or benefits due under any Benefit Plan within ten (10) days of the date
such compensation or benefits are due, or any material breach by the Company of this Agreement.

     The Executive’s right to terminate his employment for Good Reason shall not be affected by his
incapacity due to physical or mental illness.

     Notwithstanding the occurrence of any such event or circumstance, such occurrence shall not be
deemed to constitute Good Reason if (1) prior to the Date of Termination specified in the Notice of
Termination (each as defined in Sections 7(c) and 7(d)) given by the Executive in respect thereof,
such event or circumstance has been fully corrected and the Executive has been reasonably
compensated for any losses or damages resulting therefrom (provided that such right of correction
by the Company shall only apply to the first Notice of Termination for Good Reason given by the
Executive); or (2) the Company has given the Executive Notice of Termination prior to the date the
Executive provides the Company with a Notice of Termination for Good Reason.

               (b)    Termination and Compensation Upon Termination.

                 (i) Termination for Cause. The Company may terminate the Executive’s employment for
Cause.

                         (A)    If the Executive’s employment is terminated by the Company for Cause, then the Company
will pay the Executive all amounts earned or accrued hereunder through the Termination Date but not
paid as of the Termination Date, including (1) Base Salary; (2) Expenses incurred by the Executive
on behalf of the Company for the period ending on the Termination Date; (3) vacation pay (i.e. the
Base Salary divided by 260 and then

7

 

multiplied by the number of accrued and unused vacation days as
of the Termination Date); and (4) any bonus or incentive compensation with respect to the fiscal
year ended prior to the fiscal year in which the Termination Date occurs that was earned and
unpaid, (collectively, “Accrued Compensation”).

                         (B)    In the event that the Company terminates the Executive’s employment without Cause as set
forth in Section 7(b)(ii), but the Board determines subsequently that the Company had the right to
terminate the Executive’s employment for Cause pursuant to this Section 7(b)(i), the Company may
terminate the payment of all amounts to the Executive pursuant to Section 7(b)(ii) and the
Executive shall return all previous payments made to him pursuant to Section 7(b)(ii) other than
the Accrued Compensation.

                (ii) Termination by the Company Without Cause or by the Executive for Good Reason.
The Company may terminate the Executive’s employment without Cause and the Executive may terminate
his employment for Good Reason. If the Executive’s employment with the Company is terminated by
the Company without Cause (excluding any termination due to the Executive’s death or Disability) or
by the Executive for Good Reason (other than within 24 months of the Change in Control Date, in
which event Section 7(b)(v) shall apply), then the Company will pay the Executive:

                         (A)    all Accrued Compensation;

                         (B)    any deferred compensation;

                         (C)    a severance payment equal to two times the sum of (x) the Executive’s highest Base Salary
during the three-year period immediately preceding the Termination Date (or during the period the
Executive was employed by the Company, if shorter than three years) and (y) the average of the
annual bonuses awarded to the Executive pursuant to Section 3(b) above during the three-year period
immediately preceding the Termination Date (or during the period the Executive was employed by the
Company, if shorter than three years). The severance pay provided for in this section shall be paid
to the Executive in twenty-four (24) equal monthly installments on the first business day of each
month following the Termination Date except that the first payment shall not be sooner than the
eighth day following the date on which the Executive delivers to the Company the release referred
to in Section 7(b)(ii)(F) below.

                         (D)    directly, or by reimbursing the Executive for, the monthly premium for continuation
coverage under the Company’s health and dental insurance plans, to the same extent that such
insurance is provided to persons currently employed by the Company, provided that the Executive
makes a timely election for such continuation coverage under the Consolidate Omnibus Budget
Reconciliation Act of 1985 (“COBRA”). The “qualifying event” under COBRA shall be deemed to have
occurred on the Termination Date. The Company’s obligation under this paragraph shall end 18
months after the Termination Date or at such earlier date as the Executive becomes eligible for
comparable coverage under another employer’s group coverage. The Executive agrees to notify the
Company promptly and in writing of any new

8

 

employment and to make full disclosure to the Company of
the health and dental insurance coverage available to him through such new employment.

                         (E)    directly, or by reimbursing the Executive for, the monthly premium to continue the life
insurance provided for in Section 6(b) for 18 months following the Termination Date.

                         (F)    The Company shall not be obligated to make the payments otherwise provided for in Sections
7(b)(ii)(B), (C), (D) and (E) unless the Executive provides to the Company, and does not revoke, a
general release of claims in a form satisfactory to the Company.

                         (G)    The Company shall not be obligated to make the payments otherwise provided for in Sections
7(b)(ii)(B), (C), (D) and (E) upon a good faith finding by the Board of a material breach of the
Confidentiality, Non-Competition/Non-Solicitation and Work
Product Agreement incorporated by Section 8 and the Executive shall return all previous
payments made to him pursuant to Sections 7(b)(ii)(B), (C), (D) and (E) after the date on which the
Executive materially breached the Confidentiality, Non-Competition/Non-Solicitation and Work
Product Agreement incorporated by Section 8.

                (iii) Notwithstanding any other provision with respect to the timing of payments under
Sections 7(b)(ii)(B), (C), (D) and (E), to the extent that the Executive is deemed to be a “key
employee” within the meaning of Code Section 416(i), any payments to which the Executive may become
entitled under Sections 7(b)(ii) (B), (C), (D) and (E) will not commence until the first business
day of the seventh month following the Termination Date, at which time the Executive shall be paid
an aggregate amount equal to seven monthly payments otherwise due to the Executive under the terms
of Sections 7(b)(ii)(B), (C), (D) and (E). Commencing on the first business day of the eighth
month following the Termination Date and continuing each month thereafter, the Executive shall be
paid the regular monthly payment otherwise due to the Executive in accordance with the terms of
Sections 7(b)(ii) (B), (C), (D) and (E).

                (iv) Disability. The Company may terminate the Executive’s employment upon the
Executive’s Disability. If the Executive’s employment with the Company is terminated because of
his Disability, then the Company will pay the Executive (A) all Accrued Compensation; and (B) an
amount equal to the Executive’s target bonus for the fiscal year in which the Executive’s
employment is terminated due to his Disability, multiplied by a fraction, the numerator of which
shall be the number of days from the beginning of such fiscal year through the Termination Date and
the denominator of which shall be three hundred and sixty-five (365). If the Executive’s
Disability meets the definition set forth in Section 7(a)(ii)(B), the Company will also pay the
Executive any deferred compensation. In addition, effective upon the Executive’s Disability, each
outstanding option to purchase shares of Common Stock of the Company held by the Executive shall
become immediately exercisable in full and will no longer be subject to a right of repurchase by
the Company, and each outstanding restricted stock award shall be deemed to be fully vested and
will no longer be subject to a right of repurchase by the Company.

9

 

                (v) Death. The Executive’s employment shall terminate because of the Executive’s
death. If the Executive’s employment with the Company terminates because of the Executive’s death,
then the Company will pay the Executive’s beneficiaries or heirs (A) all Accrued Compensation; (B)
an amount equal to the Executive’s target bonus for the fiscal year in which the Executive’s
employment is terminated due to his death, multiplied by a fraction, the numerator of which shall
be the number of days from the beginning of such fiscal year through the Termination Date and the
denominator of which shall be three hundred and sixty-five (365); and (C) any deferred
compensation. In addition, effective upon the death of the Executive, each outstanding option to
purchase shares of Common Stock of the Company held by the Executive shall become immediately
exercisable in full and will no longer be subject to a right of repurchase by the Company, and each
outstanding restricted stock award shall be deemed to be fully vested and will no longer be subject
to a right of repurchase by the Company.

                (vi) Termination by the Company Without Cause or by the Executive for Good Reason Within
24 Months of Change in Control Date. If the Executive’s employment with the Company is
terminated by the Company without Cause (excluding any termination due
to the Executive’s death or Disability) or by the Executive for Good Reason and in either case
the Termination Date occurs within twenty-four (24) months of the Change in Control Date, then the
Company will pay or reimburse the Executive:

                         (A)    all Accrued Compensation;

                         (B)    any deferred compensation;

                         (C)    a severance payment equal to two times the sum of (x) the Executive’s highest Base Salary
during the three-year period immediately preceding the Change in Control Date (or during the period
the Executive was employed by the Company, if less than three years prior to the Change in Control
Date) and (y) the average of the annual bonuses awarded to the Executive pursuant to Section 3(b)
above during the three-year period immediately preceding the Change in Control Date (or during the
period the Executive was employed by the Company, if shorter than three years). The severance pay
provided for in this section shall be paid to the Executive in twenty-four (24) equal monthly
installments on the first business day of each month following the Termination Date except that the
first payment shall not be sooner than the eighth day following the date on which the Executive
delivers to the Company the release referred to in Section 7(b)(v)(F) below.

                         (D)    directly, or by reimbursing the Executive for, the monthly premium for continuation
coverage under the Company’s health and dental insurance plans, to the same extent that such
insurance is provided to persons currently employed by the Company, provided that the Executive
makes a timely election for such continuation coverage under COBRA. The “qualifying event” under
COBRA shall be deemed to have occurred on the Termination Date. The Company’s obligation under
this paragraph shall end 18 months after the Termination Date or at such earlier date as the
Executive becomes eligible for comparable coverage under another employer’s group coverage. The
Executive agrees to notify the Company promptly and in writing of any new employment and to make
full disclosure to the

10

 

Company of the health and dental insurance coverage available to him through
such new employment.

                         (E)    directly, or by reimbursing the Executive for, the monthly premium to continue the life
insurance provided for in Section 6(b) for 18 months following the Termination Date.

                         (F)    The Company shall not be obligated to make the payments otherwise provided for in Sections
7(b)(v)(B), (C), (D) and (E) unless the Executive provides to the Company, and does not revoke, a
general release of claims in a form satisfactory to the Company.

                         (G)    The Company shall not be obligated to make the payments otherwise provided for in Sections
7(b)(v)(B), (C), (D) and (E) upon a good faith finding by the Board of a material breach of the
Confidentiality, Non-Competition/Non-Solicitation and Work Product Agreement incorporated by
Section 8 and the Executive shall return all previous payments made to him pursuant to Sections
7(b)(v)(B), (C), (D) and (E) after the date on which
the Executive materially breached the Confidentiality, Non-Competition/Non-Solicitation and
Work Product Agreement incorporated by Section 8.

                         (H)    Notwithstanding any other provision with respect to the timing of payments under Sections
7(b)(v)(B), (C), (D) and (E), to the extent that the Executive is deemed to be a “key employee”
within the meaning of Code Section 416(i), any payments to which the Executive may become entitled
under Sections 7(b)(v)(B), (C), (D) and (E) will not commence until the first business day of the
seventh month following the Termination Date, at which time the Executive shall be paid an
aggregate amount equal to seven monthly payments otherwise due to the Executive under the terms of
Sections 7(b)(v)(B), (C), (D) and (E). Commencing on the first business day of the eighth month
following the Termination Date and continuing each month thereafter, the Executive shall be paid
the regular monthly payment otherwise due to the Executive in accordance with the terms of Sections
7(b)(v)(B), (C), (D) and (E).

                (vii) Resignation. The Executive may terminate this Agreement without Good Reason
upon thirty (30) days’ prior written notice to the Board. If the Executive’s employment with the
Company is terminated by the Executive without Good Reason, then the Company will pay the Executive
all Accrued Compensation earned through the Termination Date specified in the Notice of
Termination.

               (c)    Notice of Termination. Any purported termination by the Company or by the
Executive will be communicated by a written Notice of Termination to the other. For purposes of
this Agreement, a “Notice of Termination” means a notice which indicates the specific termination
provision in this Agreement relied upon and sets forth the Termination Date (as defined below).
For purposes of this Agreement, no purported termination of employment will be effective without a
Notice of Termination.

11

 

               (d)    Termination Date. “Termination Date” will mean (i) in the case of the Executive’s
Death, the Executive’s date of Death; (ii) if the Executive’s employment is terminated for
Disability, the date of the Executive’s Disability; (iii) if the Executive terminates his
employment, on the effective date of termination specified in the Notice of Termination; and (iv)
if the Executive’s employment is terminated for any other reason, the date specified in the Notice
of Termination, which will not be longer than seven (7) days after the Notice of Termination.

               (e)    Timing of Payment. The Accrued Compensation payable to the Executive as provided
in Sections 7(b)(i) — (vi) will be paid pursuant to applicable state law or within ten (10)
business days after the Executive’s Termination Date, whichever period is shorter. Any deferred
compensation will be paid to the Executive or his beneficiaries, as applicable, 60 days after the
Executive’s termination date. Any other compensation provided for in Section 7(b) will be paid as
set forth above.

               (f)    Mitigation. The Executive will not be required to mitigate the amount of any
payment provided for in this Agreement by seeking other employment or otherwise and no such payment
will be offset or reduced by the amount of any compensation or benefits provided to the Executive
in any subsequent employment other than as provided under Sections 7(b)(ii)(D) and 7(b)(v)(D).

               (g)    Other. The Executive’s entitlement to any other compensation or benefits upon
termination of Executive’s employment. will be determined in accordance with the Company’s employee
benefit plans and other applicable programs and practices then in effect.

     8.    Executive Covenants. As a condition of his continued employment with the Company
and in exchange for the consideration set forth in this Agreement, the Executive acknowledges and
reaffirms his obligations under his Confidentiality, Non-Competition/Non-Solicitation and Work
Product Agreement dated March 9, 2006, which shall survive the termination of his employment.

     9.    Accelerated Vesting Upon a Change in Control. If a Change in Control occurs during
the Term, then, effective upon the Change in Control:

               (a)    each outstanding option to purchase shares of Common Stock of the Company held by the
Executive shall become immediately exercisable in full and will no longer be subject to a right of
repurchase by the Company; and

               (b)    each outstanding restricted stock award shall be deemed to be fully vested and will no
longer be subject to a right of repurchase by the Company.

     10.    Treatment of Section 280G. If it is determined that the amounts payable to the
Executive under the Agreement, when considered together with any amounts payable to the Executive
in connection with a Change in Control, cause such payments to be treated as “excess parachute
payments” as defined under Code Section 280G (“Excess Parachute Payments”), and such payments equal
an amount that is at least equal to the product of (a) 3.3, multiplied by (b)

12

 

the “base amount” as
defined under Code Section 280G (“Base Amount”), then the Company will make an additional “gross
up” payment to the Executive, which shall be in an amount sufficient to pay for any additional tax
imposed on the Executive pursuant to Code Section 4999 and any additional interest or penalties
imposed on the Executive with respect to such tax, plus the federal, state and local taxes
applicable to such additional “gross up” payment. Notwithstanding the foregoing, if it is
determined that the amounts payable to the Executive under the Agreement, when considered together
with any amounts payable to the Executive in connection with a Change in Control, will cause such
payments to be treated as Excess Parachute Payments, but such payments will equal an amount which
is less than the product of (x) 3.3, multiplied by (y) the Base Amount, then the payments to the
Executive under this Agreement will be reduced to the extent necessary so that no additional tax
will be imposed on the Executive pursuant to Code Section 4999.

     11.    Successors and Assigns.

               (a)    Successor to Company. The Company shall require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the
business or assets of the Company expressly to assume and agree to perform this Agreement to the
same extent that the Company would be required to perform it if no such succession had taken place.
Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness
of any succession shall be a breach of this Agreement
and shall constitute Good Reason if the Executive elects to terminate employment, except that
for purposes of implementing the foregoing, the date on which any such succession becomes effective
shall be deemed the Date of Termination.

               (b)    Successor to the Executive. Neither this Agreement nor any right or interest
hereunder will be assignable or transferable by the Executive, his beneficiaries or legal
representatives, except by will or by the laws of descent and distribution. This Agreement will
inure to the benefit of and be enforceable by the Executive’s legal personal representative.

     12.    Arbitration. The Company and the Executive agree that they prefer to arbitrate
any dispute they may have instead of litigating in court before a judge or jury. Therefore, any
and all disputes, claims and controversies between the Company or any of its Affiliates and the
Executive arising out of or relating to this Agreement, or the breach thereof, or otherwise arising
out of or relating to the Executive’s employment or the termination thereof will be resolved by
binding arbitration in accordance with the National Rules for the Resolution of Employment Disputes
of the American Arbitration Association (or any comparable rules then in existence). The
arbitration will take place in the Boston, Massachusetts metropolitan area. The arbitrator will
have no authority to award punitive damages. The award of the arbitrator will be final and
judgment thereon may be entered in any court having jurisdiction. The parties will share the costs
of the arbitration equally, unless otherwise ordered by the arbitrator. Each party will bear its
own attorneys’ fees and costs. Judgment upon the arbitration award may be entered in any federal
or state court having jurisdiction. The parties understand and agree that EACH PARTY TO THIS
AGREEMENT WAIVES ANY RIGHT TO A JURY TRIAL.

13

 

     13.    Notice. For the purposes of this Agreement, notices and all other communications
provided for in the Agreement (including the Notice of Termination) will be in writing and will be
deemed to have been duly given when personally delivered or sent by certified mail, return receipt
requested, postage prepaid, addressed to the respective addresses last given by each party to the
other, provided that all notices to the Company will be directed to the attention of the Board with
a copy to the Secretary of the Company. All notices and communications will be deemed to have been
received on the date of delivery thereof or on the third business day after the mailing thereof,
except that notice of change of address will be effective only upon receipt.

     14.    Non-exclusivity of Rights. Nothing in this Agreement will prevent or limit the
Executive’s continuing or future participation in any benefit, bonus, incentive or other plan or
program provided by the Company or any of its subsidiaries and for which the Executive may qualify,
nor will anything herein limit or reduce such rights as the Executive may have under any other
agreements with the Company or any of its subsidiaries. Amounts which are vested benefits or which
the Executive is otherwise entitled to receive under any plan or program of the Company or any of
its subsidiaries will be payable in accordance with such plan or program, except as explicitly
modified by this Agreement.

     15.    Miscellaneous. No provision of this Agreement may be modified, waived or
discharged unless such waiver, modification or discharge is agreed to in writing and signed by the
Executive and the Company. The Company and the Executive agree that they will negotiate in good
faith and jointly execute an amendment to modify this Agreement to the extent necessary to comply
with the requirements of Code Section 409A, or any successor statute, regulation and
guidance thereto; provided that no such amendment shall increase the total financial
obligation of the Company under this Agreement. No waiver by either party hereto at any time of
any breach by the other party hereto of, or compliance with, any condition or provision of this
Agreement to be performed by such other party will be deemed a waiver of similar or dissimilar
provisions or conditions at the same or at any prior or subsequent time. No agreement or
representations, oral or otherwise, express or implied, with respect to the subject matter hereof
have been made by either party which are not expressly set forth in this Agreement.

     16.    Governing Law. This Agreement will be governed by and construed and enforced in
accordance with the laws of the Commonwealth of Massachusetts without giving effect to the conflict
of law principles thereof. The Executive hereby irrevocably submits and acknowledges and
recognizes the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate,
a federal court located in Massachusetts (which courts, for purposes of this Agreement, are the
only courts of competent jurisdiction), over any suit, action or other proceeding arising out of,
under or in connection with this Agreement or the subject matter hereof.

     17.    Severability. The provisions of this Agreement will be deemed severable and the
invalidity or unenforceability of any provision will not affect the validity or enforceability of
the other provisions hereof.

     18.    Entire Agreement. This Agreement, and the Non-Competition Agreement, the

14

 

2000
Stock Incentive Plan, the PolyMedica Corporation Executive Savings Plan and the PolyMedica
Corporation Employee Stock Purchase Plan constitute the entire agreement between the parties hereto
and supersede all prior agreements, understandings and arrangements, oral or written, between the
parties hereto with respect to the subject matter hereof, including, but not limited to, the Prior
Agreements.

     19.    Tax Consequences. The Company does not guarantee the tax treatment or tax
consequences associated with any payment or benefit arising under this Agreement.

[Remainder of Page Intentionally Left Blank]

15

 

     IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly
authorized officer and the Executive has executed this Agreement as of the day and year first above
written.

	 	 	 	 	 
	 	PolyMedica Corporation

 	 
	 	/s/ Stephen C. Farrell
 	 
	 	Name:  	Stephen C. Farrell 	 
	 	Title:  	Chief Operating Officer 	 
	 
	 	Executive

 	 
	 	/s/ Keith W. Jones
 	 
	 	  	 	 
	 	  	 	 
	 

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]